Table 1 Clinical characteristics of the study participants
Vonoprazan group n = 85 | Lansoprazole group n = 83 | P value | |
|---|---|---|---|
Age (years), median (range) | 73 (47–89) | 73 (33–90) | 0.96 |
Sex, male, n (%) | 63 (74) | 58 (70) | 0.54 |
Habits | |||
Smoking, n (%) | 16 (19) | 16 (19) | 0.94 |
Alcohol, n (%) | 36 (42) | 34 (41) | 0.86 |
Anti-Helicobacter pylori IgG antibody | |||
Positive, n (%) | 30 (35) | 31 (37) | 0.78 |
*PPI use prior to treatment | |||
Yes, n (%) | 24 (28) | 18 (22) | 0.33 |
Comorbidities | |||
Hypertension, n (%) | 56 (66) | 44 (53) | 0.089 |
Diabetes mellitus, n (%) | 18 (21) | 14 (17) | 0.48 |
Ischemic heart disease, n (%) | 0 (0) | 2 (2) | 0.24 |
Cerebral infarction, n (%) | 0 (0) | 1 (1) | 0.49 |
Location of lesion | |||
Upper third, n (%) | 9 (11) | 11 (13) | 0.28 |
Middle third, n (%) | 35 (41) | 42 (51) | |
Lower third, n (%) | 41 (48) | 30 (36) | |
Lesion size (mm), median (range) | 10 (2–54) | 10 (2–40) | 0.85 |
Preoperative histological diagnosis | |||
Adenoma, n (%) | 19 (22) | 27 (32) | 0.20 |
Differentiated adenocarcinoma, n (%) | 64 (75) | 52 (63) | |
Undifferentiated adenocarcinoma, n (%) | 2 (2) | 2 (2) | |
Neuroendocrine tumor grade 1, n (%) | 0 (0) | 2 (2) | |
Ulcer scar in tumor, n (%) | 6 (7) | 7 (8) | 0.74 |
†ESD ulcer index (mm2), median (range) | 875 (260–4000) | 875 (238–4180) | 0.59 |